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1. To systematically review the currently available evidence investigating the association between 
olfactory dysfunction (OD) and the novel coronavirus (COVID-19). 
2. To analyse the prevalence of OD in patients who have tested positive on Polymerase Chain Reaction 
(PCR) for COVID-19. 
2. To perform a meta-analysis of patients presenting with olfactory dysfunction, during the pandemic, 
and to investigate the Positive Predictive Value for a COOVID-19 positive result in this population. 
3. To assess if olfactory dysfunction could be used as a diagnostic marker for COVID-19 positivity and aid 
public health approaches in tackling the current outbreak. 
Methods 
We systematically searched MedLine (PubMed), Embase, Health Management Information Consortium 
(HMIC), Medrxiv, the Cochrane Library, the Cochrane COVID-19 Study Register, NIHR Dissemination 
centre, Clinical Evidence, National Health Service Evidence and the National Institute of Clinical 
Excellence to identify the current published evidence which associates coronaviridae or similar RNA 
viruses with anosmia. 
The initial search identified 157 articles. 145 papers were excluded following application of our exclusion 
criteria. The 12 remaining articles, that presented evidence on the association between COVID-19 and 
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OD has been shown to be the strongest predictor of COVID-19 positivity when compared to other 
symptoms in logistic regression analysis. In patients who had tested positive for COVID-19 there was a 
prevalence of 62% of OD. In populations of patients who are currently reporting OD there is a positive 
predictive value of 61% for a positive COVID-19 result. 
Conclusion 
Our review has shown that there is already significant evidence which demonstrates an association 
between OD and the novel coronavirus – COVID-19. It is unclear if this finding is unique to this 
coronavirus as individual viral phenotypes rarely present in such concentrated large numbers. We have 
demonstrated that OD is comparatively more predictive for COVID-19 positivity compared to other 
associated symptoms. We recommend that people who develop OD during the pandemic should be self-
isolate and this guidance should be adopted internationally to prevent transmission. 
Introduction 
There was already a wealth of anecdotal evidence that suggested olfactory dysfunction(OD)was 
animportant symptom in patients who had contracted the novel SARS-CoV-2 coronavirus (COVID-19) 
prior to the main outbreak in the United Kingdom. Initial reports made in newspapers from Germany 
indicated that as many as two thirds of cases of COVID-19 reported loss of smellwhilst in South 
Korea,15.3% of patients who have tested positive had perceived disturbance of smell or taste(1). Since 
these initial reports a number of studies have demonstrated a clear association between OD and COVID-
19. This is the first worldwide pandemic where reporting of symptoms, aided by social media and 
telecommunication systems, has been shared so widely. High profile public figures have reported both 
symptoms which has led to widespread interest in the symptoms across both the press and the public(2).  
It has previously been demonstrated that the geneticallysimilar SARS-CoVvirus can spread via a synapse-
connected route to the medullary cardiorespiratory centre(3).Coronaviral RNA has been identified post 
mortem concentrated in the brain-stem of human patients during the previous SARS-CoV pandemic, and 
studies in mice have shown that previously described corona viruses can invade intracranially when 
administered intranasally indicating that the virus may travel via the olfactory nerves.Helms et al present 
a series of patients infected during the current COVID-19 outbreak and demonstrate numerous 
neurological sequelae and abnormalities on cross-sectional imaging of the brain(4). 
Brann et al (in a paper made available prior to peer review) have identified non-neuronal cell types, such 
as sustentacular and olfactory stem cells as well as horizontal basal cells are the potential target of 
COVID-19 in the human olfactory epithelium via the ACE2 receptor and the spike protein protease 
TMPRSS2. This presents three main theories for potential loss of smell in COVID-19. Firstly, a local 
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escalating damage to the architectural structure of the entire olfactory epithelium, due to damage to 
sustentacular cells and Bowman’s glands(5) .  
Viral upper respiratory tract infection (URTI) is one of the known major identifiable causes of olfactory 
dysfunction (OD) due to the degeneration of olfactory epithelium(6).Due to the widespread and insidious 
nature of viral URTI there is no data relating to the incidence of post-viral OD for specific viruses but post-
viral cases typically account for 11% of all cases of OD in the community(7) with cases presenting to 
specialist clinics typically representing 20% of cases (8). This group is often represented as a higher 
proportion in online surveys and patient fora at around 30%(9)(10). Patients often present to the 
Otolaryngologist in persistent cases but those that resolve soon after the infective process has subsided 
are likely rarely reviewed or reported(11).  
BMJ best practice have recently published an update on Coronavirus and the range of symptoms that are 
associated with this. They quote the anecdotal evidence published by ENT UK(1) and the American 
Academy of Otolaryngology(12)regarding the link between anosmia and coronavirus. Both these 
international bodies have  recommended self-isolation for patients who develop these 
symptoms(13)Fortunately following lobbying by ENT UK and the British Rhinological Society(BRS)OD has 
now been incorporated in to national  public health policy with Public Health England (PHE) following the 
WHO in recognising loss of smell and taste as a key symptom of covid-19 infection (2) .  
The aim of this systematic review and metanalysis is to identify the currently available evidence for the 
relationship between COVID-19 and self-reported loss of smell. This will include assessing the potential 
for OD as a diagnostic marker in COVID-19, outlining the current peer-reviewed evidence relating to this 
relationship and how it can be utilised going forwards in clinical practice. 
We decided to focus on OD and not include loss of taste in this review. OD will lead to reduced retronasal 
olfaction and subsequently impact the perception of taste in these patients. Flavour perception involves 
input from ortho and retronasal olfaction and gustation, complemented by trigeminal stimulation 
through touch and pain fibres. Patients typically find it difficult to isolate true gustatory sensations from 
retronasal olfaction without objective gustatory testing(14) . Given the difficulties in interpreting this 
symptom, in the absence of more detailed questions regarding taste perception, we decided to solely 
review OD.  
Methods 
We systematically searched MedLine (PubMed), Embase, the Health Management Information 
Consortium (HMIC),Medrxiv,the Cochrane Library, the Cochrane COVID-19 Study Register, NIHR 
Dissemination centre, Clinical Evidence, National Health Service Evidence and the National Institute of 
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RNA viruses with anosmia.The search strategy for MedlineandEmbase are demonstrated in Appendix 1. 
The final search was undertaken in 18th April 2020. We included all years and all languages in the search.  
The initial search identified 157 articles. 145 articles were excluded as they did not investigate a link 
between the current coronavirus outbreak and OD, were conference abstracts, isolated case reports or 
did not have an English version available. The literature search is presented in the Prisma flow diagram 
(Figure 1). One case series presented loss of smell and taste in combination, where patients were 
included if they had experienced either symptom. As such we were unable to isolate olfactory 
dysfunction in their population. Reporting related but independent symptoms in this way prevents formal 
analysis of their individual epidemiological factors and impact on patient outcomes.  
We used the ROBINS-E (Risk of Bias in Non-randomised Studies – of Exposures) tool to assess the studies 
for bias. The articles were assessed across 7 parameters; confounding factors, selection of participants, 
classification of exposures, departures from intended exposures, missing data, measurement of 
outcomes and the reported result. All the studies were assessed at “serious” risk of bias due these 
common themes; lack of adjustment for confounding variables, differences in follow up and the start of 
exposure, variation in reporting, and numerous different subgroups reported.   
Results  
1. Methodology 
There were 12articlesthat have investigated the association between COVID-19 and OD. The studies vary 
in their methodology and in the patient populations that they target. A summary of the studies 
evaluated, their study methodology and the quality of the evidence is presented below in Table 1. Several 
of the studies had not completed the peer review process and this status is also demonstrated in the 
table.  
Table 1 
2. Description of studies 
2.1 Cross-sectional Questionnaire 
The most common methodology for assessment in the articles searched was a cross-sectional 
questionnaire which were conducted over a variety of mediums i.e. face to face, mobile applicationor 
web-based forms.The cohort of patients targeted also varied between inpatient and outpatient 
populations and in their geographical location (Tables 2 and 3). Whilst there are clear limitations to this 
approach and it is not possible to demonstrate a direct causal relationship between COVID-19 and ODbut 
they are able to present associations in the symptomatology of this pandemic.  
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The majority of the remaining studies present case series. They present similar cross-sectional evidence 
to the questionnaire designed studies with a common aim of investigating the symptomatology of 
anosmia in the COVID-19 era. This approach should contribute to limiting the level of bias in their results 
when compared to an outcome-based case series but they are similarly only able to demonstrate 
association and not causal effect. The complementary data output, between the questionnaire and case-
series approaches, allows us to compare the two approaches concurrently in a meta-analysis.  
2.3 Search Term Analysis  
Walker et al were unique in their approach and used Google Trends to track search terms related to loss 
of smell. They demonstrate statistically significant association of the Google search terms and 
theincidence of COVID-19 cases and deaths. The previous figures for the same time period in 2019 and 
the H1N1 pandemic were used as controls. This correlation was present across numerous countries 
including Italy, Spain, the United Kingdom (UK), the United States of America (USA), Germany, France, 
Iran and the Netherlands. They propose that this technique could be used to track disease hot spots 
internationally where targeted control measures could then be implemented. For this to be effective 
there needs to be clear data on the positive predictive value of new onset anosmia and COVID-19 
positivity(15).  
2.4 Case Control Study 
In the only study so far to institute validated quantitative olfactory testing Moein et al, in Iran, evaluated 
60 patients who had tested positive for COVID-19. Their control group were selected from a group of 141 
controls from a previously conducted study. They handpicked age and sex matched individuals from this 
cohort in an attempt to mirror their COVID-19 positive group. COVID-19 patients completed the Persian 
version of the 40-odorant University of Pennsylvania Smell Identification Test (UPSIT) assisted by a 
trained examiner, they do not explain how they administered the test in their previously investigated 
control group. Ninety-eight percent of their COVID-19 group had some level of OD with 25% of these 
subjects being completely anosmic. There was a statistically significant reduction in scores, in all 40 
stimuli, within the COVID-19 group. There were no differences in demographics between the two groups 
but the way the control group was matched will have affected this data(16) .  
3 Risk of Bias and Limitations  
When analysing data related to COVID-19 positivity it is important to recognise the sensitivity of the test 
is variable. Bronchoalveolar lavage is the most sensitive test (93%) whilst nasal swabs (63%) and 
pharyngeal swabs (46%) have lower positive rates14. Moein et al, who conducted the UPSIT, case control 
study and Mao et al were the only authors to report the technique and anatomical location of their 
Polymerase Chain Reaction (PCR) analysis of COVID-19 status. Moien et al used nasal aspirates or washes 
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there will be a proportion of false negatives that will falsely lower the incidence of COVID-19 positivity in 
the OD groups and will therefore also impact on the calculation of sensitivity and specificity.  
The majority of the responses to questionnaires were received remotely using electronic response forms 
of mobile based applications which will cause selection bias. Younger more technologically interactive 
cohort are more likely to interact and this sub-group seem to be less affected by COVID-19 when 
compared to older age groups who have a higher morbidity and mortality(18). For example, Menni et al, 
who used a mobile based application, report an average age of 41.48 (CI = 13.77) for those in their non-
PCR-tested group, including over 1.5million people(19). Hospitalised populations are also less likely to 
interact with these methods due to their disease severity, internet connection or associated 
interventional treatments. 
Cross-sectional questionnaires and case series are prone to bias due to influence of confounding 
variables, assessment of patients at different time points relative to their exposure and reporting bias. In 
case series specifically consecutive patients often missed in data collection.  In these studies, however 
the researchers are simply presenting patient factors and associated symptoms rather than treatments or 
interventions and their subsequent effects or outcomes and this observational nature could help to 
reduce observer bias. In studies that were conducted requiring historical data from the patients there is a 
risk of recall bias and under-reporting or inaccuracies of symptoms specifically where onset and duration 
of symptoms is involved.  
4. Comparing COVID positive and Olfactory Dysfunction Populations 
Two distinct populations havebeen assessedin the literature. The first groupwere those patients who had 
received testing and were confirmed positive COVID-19 patients, the prevalence of OD was then 
analysed. The second were people who had experienced OD and the prevalence of COVID-19 within this 
cohort. Menni et aland Yan et alreport data from both groups concurrently and presented data for both 
populations in their results(19,20).  
4.1 Prevalence of Olfactory Dysfunction in COVID-19 Positive Patients 
Menni et al used the “COVID RADAR” symptom tracker app to extract a cohort of patients who had 
tested positive for COVID-19and their associated symptomatology. Nearly 2.5million people reported 
symptoms on this app butonly 15638, were tested and 6452 tested positive. This small proportion of their 
total population, and limited case definition used for access to testing at the time of the study, and risk of 
false negatives were the main limitations of this study. They then analysed the COVID-19 positive and 
negative groups for prevalence of symptoms. In the COVID-19 positive group 64.76% had experienced 
loss of smell compared to 22.68% in the negative group. For patients reporting loss of smell they report 
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sex and body mass index. In their model loss of smell and taste was the strongest predictor of a COVID-19 
positive result(19).  
Lechian et al’s multi-centre study analysedpatient and volunteer health care professionals’who had a PCR 
positive result for COVID-19 with a questionnaire. Patients in the intensive care unit, patients with 
previous OD and those without a COVID-19 PCR result were excluded from analysis. The impact of ODwas 
evaluated using a quality of life tool (sQOD-NS). 85.6% of their cohort of 417 patients reported OD. The 
majority self-rated as anosmic (79.6%) but others experienced hyposmia, phantosmia and parosmia. 
Anosmic patients were found to have a significantly lower sQOD-NS score compared with the hyposmic 
and normosmic individuals. This OD was not significantly associated with rhinorrhoea or nasal obstruction 
but a significant association was found with females being proportionally more affected than males. In 
the subgroup of patients who had clinically resolved infection the OD persisted in 63% of cases(21).  
Yan et al sent an email invitation to complete a survey to 1480 patients who had undergone COVID-19 
testing. They had a 58% response from COVID-19 positive patients and a 15% response from the negative 
group. Their survey evaluated patient reported symptoms with a focus on smell and taste. Sixty-eight 
percent of the COVIVD-19 positive group reported OD and similarly to Menni et al they found that loss of 
sense of smell (and taste) showed the largest magnitudes of association to COVID-19 positivity when 
compared with other symptoms. Seventy-two percent of the COVID-19 positive patients with OD 
reported improvement at the time of the survey(20) .  
Mao et al were one of the first groups to present the symptomatology of patients presenting with a 
positive COVID-19 swab result. 5.1% of this group of 214 patients had experienced hyposmia. This was a 
retrospective analysis of electronic patient data and as such there is a risk that OD was not a symptom 
explored or documented in individual consultations within this cohort of patients. According to a 
“diagnostic criteria” that is not described they divided their patients in to severe and non-severe groups. 
Of the 11 patients who had reported hyposmia 3 were non-severe and 8 were severe(17).  
Giacomelli et al interviewed 59 of 88 inpatients with COVID-19 demonstrated on PCR, there were 29 non-
respondents due to receiving ventilation, dementia and linguistic barriers. They report combined rates of 
smell or taste disturbance and as such comparative incidence rates solely for OD was not possible to 
produce from the data presented. In their cohort the olfactory and gustatory disorders occurred in 
proportionally younger and more commonly female subjects and no patients had recovered at the time 
of interview. No data relating to time of interview following onset of symptoms is reported(22) .  
In the studies that investigated olfactory symptoms independently we present the prevalence rates in 
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4.2 Prevalence of COVID-19 in New Onset Olfactory Dysfunction Cohorts  
Due to the differences in public health approaches and the availability of testing it is difficult to 
demonstrate clear associations between new onset OD and COVID-19 positivity. There were however 
three studies that did have PCR results for patients presenting with ODsince the start of the COVID-19 
pandemic. In table 2 we demonstrate that there is a high prevalence of COVID-19 positivity in patients 
currently presenting with OD.  
The American Academy of Otolaryngology – Head and Neck Surgery (AAO-HNS) developed a COVID-19 
Anosmia reporting tool for clinicians. Responses were collected from clinicians around the world relating 
to the association of COVID-19 and anosmia. They do not clearly state if all submitted patients had PCR 
testing performed. 237 entries were analysed; anosmia was the initial symptom in more than 25% of 
cases, 27% had noticed some improvement and in 40% was the symptom that led to a test being 
performed(23).  
Bagheri et al conducted a widely completed online survey, of the general population in Iran, to identify 
patients with OD since the inception of the outbreak in their country. They demonstrated high numbers 
of people who had experienced OD in their cohort. Their respondents were commonly female (71%) and 
experienced sudden onset in their OD (76%). Only 1.1% were admitted to hospital for treatment 
indicating a largely mild disease when OD was experienced(24). In a similar online questionnaire study, 
conducted in the UK, by Hopkins et al the demographic features were replicated. The majority of this 
British population with ODreported complete loss of smell (74.4%) and in 16% of cases it was their only 
symptom. A proportion of these patients did report receiving a PCR test with a 74% positive rate in this 
sub-group(25).   
Gane et al present a case series of 11 patients presenting with sudden onset anosmia during the 
epidemic in the United Kingdom. In 5 of these patients it was an isolated symptom and just one of these 
patients were self-isolating(26). Gengler et al present findings(in an unpublished paper made available 
before peer review) from a French case series, not currently published, which demonstrated a positive 
COVID-19 nasal PCR swab in 94% of their 55-patient series(27).  
Table 3 demonstrates the average ages and gender proportions of the six studies with ODcohorts.  
Table 3 
Discussion 
Our review has shown that there is already significant evidence which demonstrates an association 
between OD and the novel coronavirus – COVID-19. It is unclear if this finding is unique to this 
coronavirus as individual viral phenotypes rarely present in such concentrated large numbers. Classically 
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symptomatology during the infective phase of the virus has not previously been studied and therefore it 
is not possible to draw direct comparison between other similar viruses. Walker et al have however 
demonstrated trends between increasing cases of COVID-19 and the increase in positive novel 
coronavirus cases that was not mirrored during the previous H1N1 pandemic in 2009(15).  
Due to the rapid spread of COVID-19 in this pandemic it is understandable that there is a lack of studies 
using objective measures and rigorous controls. The most common methodologies used were cross-
sectional questionnaires and case series. These approaches are at risk of bias and we can only discuss 
associations as a result. Further research will be required to demonstrate clearer links between OD and 
COVID-19 going forwards.  
When we assessedpatients who had experienced OD during the outbreak there were several studies that 
demonstrated an increase in the prevalence of loss of smell in their populations when compared to 
previous estimates(19,24,25). The largest data sets, conducted predominantly in the outpatient setting, 
by Hopkins and Bagheri et al indicated a female preponderance in their cohorts (73% and 71% 
respectively). These two studies also demonstrated an average affected age between 30-40. It has been 
demonstrated that both advanced age and the male sex are risk factors for the severe form of the disease 
and an increased rate of mortality(18). It could be that this cohort of patients were not targeted by this 
study due to the more elderly populations not interacting with web-based surveys or being within the 
inpatient population due to their disease severity. Moein et al demonstrated in their study of inpatients 
that OD was a common finding in this population too when they applied objective UPSIT testing to 
confirmed cases(16). Further research is needed to identify if the incidence of ODvaries between 
different ages and genders and as such if particular disease phenotypes for COVID-19 can give clinicians 
prognostic information.  
In areas where testing has not been adopted widely tracking of this ODcould be vital in identifying hot-
spots where population-based management strategies can then be targeted. Tracking OD using mobile-
based applications, such as the one developed by Menni et al, will allow real time data tracking for aid 
models in the prediction of national or regional COVID-19 cases(19). This approach could lead to specific 
social distancing measures being implemented in areas where OD is wide-spread and will also help in 
modelling when these measures could be relaxed as most patients seem to recover their sense of smell 
following the illness.  
 
Conclusion 
Our meta-analysis has demonstrated that the prevalence of OD in patients who have a positive PCR test 
for COVID-19 is 62%. OD was demonstrated to be the most strongly associated symptom, for a positive 
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OD and had received PCR swab there was a positive predictive value of 61% for a positive result. The 
evidence to support an association between OD and COVID-19 continues to grow. The symptom has now 
been recognised by the World Health Organisation and Public Health England (29) . This change in 
approach should mean an increase in the number of positive COVID-19 cases self-isolating and a 
subsequent reduction in the chance of spread with benefits for public health and containment of the 
pandemic.   
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Table 1: Summary of Papers in Review 
Article Title Primary Author Methodology Peer review 
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Real-time tracking of self-reported 
symptoms to predict potential COVID-19 





Olfactory and gustatory dysfunction as a 
clinical presentation of mild-to-
moderate forms of the coronavirus 
disease: a multicentre European Study 
J Lechian Cross sectional 
questionnaire 
Yes 
Self reported olfactory and taste 







Coincidence of COVID-19 Epidemic and 
olfactory dysfunction outbreak 
S Bagheri Cross sectional 
questionnaire 
Yes 
Presentation of new onset anosmia 
during the COVID-19 pandemic 
C Hopkins Cross sectional 
questionnaire 
Yes 
Association of Chemosensory 
Dysfunction in COIVD-19 Patients 
Presenting with Influenza- like 
Symptoms 
C Yan Cross sectional 
questionnaire 
Yes 
COVID-19 Anosmia Reporting Tool: 
Initial Findings 
R Kaye Clinician Reporting Tool 
/ Cross sectional 
questionnaire 
Yes 
Isolated sudden onset anosmia in 
COVID19 infection. A novel syndrome 
S Gane Case Series Yes 
Neurological Manifestations of 
Hospitalised Patients with COVID-19 in 
Wuhan , China: a retrospective case 
series study 
L Mao Case Series Yes 
Sinonasal pathophysiology of SARS CoV 
2 and COVID19: a systematic review of 
the current evidence 
I Gengler Case series reported 
within SR  
Systematic Review 
published but 
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The Use of Google Trends to Investigate 
the loss of smell related searches during 
the COVID-19 outbreak 
A Walker Search Term Analysis Yes 
Smell dysfunction: A Biomarker for 
COVID-19 
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Table 2: Meta-analysis of patients with COVID-19 positive PCR result and prevalence of Olfactory 
Dysfunction 















C Menni 579 344 59% 41 69% Outpatient 
based 
UK based 






C Yan 59 40 68% No data No data Outpatient 
based 
USA 
ST Moein 60 58 97% 47 33% Inpatient Iran 
L Mao 214 11 5% No data No data Inpatient China 
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Table 3: Meta-analysis of patients with new onset olfactory dysfunction and prevalence of COVID-19 
positivity  











Female Setting Location 
S Bagheri 10069 No data No data 32.5 71% Outpatient 
based 
Iran 
S Gane 11 No data No data 37.6 27% Outpatient UK 













I Gengler* 55 52 94% No data No data No data France 
 
C Yan 73 40 55% No data No data Outpatient 
based 
USA 
C Menni 557 345 62% No data No data Outpatient 
based 
UK 
Underlined values where patients with olfactory dysfunction were PCR tested for COVID-19 and included in 
meta-analysis below (Yan et al, Menni et al):  










From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097 
 
For more information, visit www.prisma-statement.org. 
 
Prisma 2009 Flow Diagram: Olfactory Dysfunction in COVID-19 
ta 
Records identified through 
database searching 


































Additional records identified 
through other sources 
(n = 3) 
Records after duplicates removed 
(n = 157)  
Records screened 
(n = 157) 
Records excluded 
(n = 141) 
• Non-relevant titles 
• Non-relevant abstracts 
• Case reports 
Full-text articles assessed 
for eligibility 
(n = 16) 
Full-text articles excluded, 
with reasons 
(n = 3) 
• Research protocol = 1 
• Poor quality review of 
anecdotal evidence = 1 
• Poor research 
methodology not 
specific to anosmia = 2 
 
Studies included in 
qualitative synthesis 
(n =12) 
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